Go Deep
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,594 | -13.5 | 0.69 | 0.07 | 219.04 |
| Oct 2026 | 21,691 | -13.0 | 0.66 | 0.07 | 209.83 |
| Oct 2026 | 21,529 | -14.8 | 0.70 | 0.07 | 224.11 |
| Oct 2026 | 21,723 | -12.8 | 0.65 | 0.07 | 206.48 |
| Oct 2026 | 21,658 | -13.2 | 0.67 | 0.07 | 212.39 |
| Oct 2026 | 21,551 | -13.8 | 0.70 | 0.07 | 221.87 |
| Oct 2026 | 21,701 | -12.9 | 0.66 | 0.07 | 208.08 |
| Oct 2026 | 21,583 | -13.6 | 0.69 | 0.07 | 218.04 |
Rocket Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 123,214,000.0 | -47,594,000.0 | -42,538,000.0 | -50,332,000.0 |
| EPS | 1.1 | -0.4 | -0.4 | -0.5 |
Rocket Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -223,123,000.0 | -258,746,000.0 | -245,595,000.0 | -221,863,000.0 | — |
| EPS | -2.0 | -2.7 | -2.9 | -3.3 | — |
Rocket Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 330,449,000.0 | 527,700,000.0 | 566,341,000.0 | 551,807,000.0 | — |
| Total Liabilities | 53,228,000.0 | 64,466,000.0 | 73,767,000.0 | 62,121,000.0 | — |
| Total Equity | 277,221,000.0 | 463,234,000.0 | 492,574,000.0 | 489,686,000.0 | — |
Owes vs Owns
Rocket Pharmaceuticals, Inc. owed $0.13 for every $1 it owned in Jun 2026, up from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.13× | 0.16× | 0.12× | 0.13× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Rocket Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 57.2%Fixed assets (tangible) 21.7%Intangible assets 19.5%Other assets 1.7%
How it's funded — Dec 2025
Short-term debt 0.9%Long-term debt 6.6%Other liabilities 8.6%Shareholders' equity 83.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 188.9 | 372.3 | 373.2 | 356.4 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 71.6 | 83.3 | 87.6 | 77.6 |
| Intangible assets | 64.3 | 64.3 | 64.3 | 64.9 |
| Long-term investments | 0.0 | 0.0 | 34.3 | 43.3 |
| Other assets | 5.6 | 7.7 | 7.0 | 9.6 |
| Liabilities & equity | ||||
| Short-term debt | 2.9 | 2.9 | 2.7 | 2.5 |
| Long-term debt | 22.0 | 22.6 | 22.3 | 20.4 |
| Payables | 0.0 | 25.9 | 13.1 | 0.6 |
| Other liabilities | 28.3 | 13.1 | 35.6 | 38.7 |
| Shareholders' equity | 277.2 | 463.2 | 492.6 | 489.7 |
| Net tangible assets | 212.9 | 398.9 | 428.3 | 424.8 |
Rocket Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -190,014,000.0 | -209,724,000.0 | -194,916,000.0 | -178,142,000.0 | — |
| Investing Activities | 103,767,000.0 | 131,706,000.0 | -98,066,000.0 | -69,326,000.0 | — |
| Financing Activities | 148,000.0 | 185,739,000.0 | 208,401,000.0 | 155,288,000.0 | — |